Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ecaterina Ileana-Dumbrava

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Cold Spring Harbor Molecular Case Studies|December 8, 2017
Personalized cancer therapy-leveraging a knowledge base for clinical decision-makingEcaterina Ileana Dumbrava, Funda Meric-Bernstam
Journal of Immunotherapy and Precision Oncology|June 6, 2022
Tumor Genotype Is Shaping Immunophenotype and Responses to Immune Checkpoint Inhibitors in Solid TumorsKathrina L Marcelo-Lewis, Shhyam Moorthy, Ecaterina Ileana-Dumbrava
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 23, 2018
Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment With Ipilimumab and Radiation TherapyEcaterina Ileana Dumbrava, Veronica Smith, Rasha Alfattal, et al.
Oncotarget|March 28, 2020
Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN lossNicci Owusu-Brackett, Ming Zhao, Argun Akcakanat, et al.
Oncotarget|September 7, 2019
TAK228 enhances antitumor activity of eribulin in triple negative breast cancerNicci Owusu-Brackett, Kurt W Evans, Argun Akcakanat, et al.
Experimental Hematology & Oncology|April 28, 2020
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trialVivek Subbiah, Ecaterina Ileana Dumbrava, Yunfang Jiang, et al.
Scientific Reports|January 25, 2022
Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterationsSeyed Pairawan, Argun Akcakanat, Scott Kopetz, et al.
Breast Cancer Research : BCR|March 5, 2021
First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer modelsSeyed Pairawan, Ming Zhao, Erkan Yuca, et al.
Nature Reviews. Clinical Oncology|January 6, 2026
The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncologyAmber Johnson, Yifei Shen, Xiaofeng Zheng, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Cold Spring Harbor Molecular Case Studies|December 8, 2017
Personalized cancer therapy-leveraging a knowledge base for clinical decision-makingEcaterina Ileana Dumbrava, Funda Meric-Bernstam
Journal of Immunotherapy and Precision Oncology|June 6, 2022
Tumor Genotype Is Shaping Immunophenotype and Responses to Immune Checkpoint Inhibitors in Solid TumorsKathrina L Marcelo-Lewis, Shhyam Moorthy, Ecaterina Ileana-Dumbrava
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 23, 2018
Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment With Ipilimumab and Radiation TherapyEcaterina Ileana Dumbrava, Veronica Smith, Rasha Alfattal, et al.
Oncotarget|March 28, 2020
Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN lossNicci Owusu-Brackett, Ming Zhao, Argun Akcakanat, et al.
Oncotarget|September 7, 2019
TAK228 enhances antitumor activity of eribulin in triple negative breast cancerNicci Owusu-Brackett, Kurt W Evans, Argun Akcakanat, et al.
Experimental Hematology & Oncology|April 28, 2020
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trialVivek Subbiah, Ecaterina Ileana Dumbrava, Yunfang Jiang, et al.
Scientific Reports|January 25, 2022
Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterationsSeyed Pairawan, Argun Akcakanat, Scott Kopetz, et al.
Breast Cancer Research : BCR|March 5, 2021
First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer modelsSeyed Pairawan, Ming Zhao, Erkan Yuca, et al.
Nature Reviews. Clinical Oncology|January 6, 2026
The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncologyAmber Johnson, Yifei Shen, Xiaofeng Zheng, et al.
Pageof 1